- CSR Summary Not Yet Available
- NCT01790126
- Primary Citation Trial has yet to be published
Trial Information
Generic NameApalutamideProduct NameERLEADA®Therapeutic AreaCancers and Other NeoplasmsEnrollment90% Female0.0%% White90.0%
Product ClassAndrogen Receptor InhibitorsSponsor Protocol NumberARN-509-002Data PartnerJohnson & JohnsonCondition StudiedProstate CancerMean/Median Age (Years)67.0
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available